

Supplementary Figure S1: Study schematic showing patient disposition in both treatment groups



Supplementary Figure S2: Time from the start of sorafenib to progression on sorafenib in patients receiving sorafenib only, or sorafenib followed by second-line nivolumab treatment



Supplementary Figure S3: Survival analysis of overall cohort of patients on the basis of A) CTP class and by B) BCLC stage